ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1443

A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis

Daniel Zimmerman1, Harold Steiner III1, Roy Carambula1, Adrienn Markovics2, Alison Finnegan3, Katalin Mikecz2 and Tibor Glant4, 1Research and Development, Cellular Immunology, CEL-SCI Corporation, VIENNA, VA, 2Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 3Dept of Medicine, Rush University Med Ctr, Chicago, IL, 4Orthopedic Surgery, Rush Med Ctr Cohn Bldg Rm 708, Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Arthritis, proteoglycans, therapeutic targeting and vaccines

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatoid arthritis (RA) is an autoimmune disease leading to inflammatory destruction of the peripheral joints. Although pro-inflammatory T helper 1 (Th1) and/or Th17 cell responses play a central role in the immunopathology of RA, current therapies do not provide efficient inhibition of these pro-inflammatory T cells or their signature cytokines. In this study, we demonstrate that the peptide conjugate DerG-PG70 (CEL-4000) is able to inhibit Th1 and Th17 responses and can act as a therapeutic vaccine in an autoimmune mouse model of RA.

Methods:  Female BALB/c mice were immunized intraperitoneally (ip) with the recombinant G1 domain of human cartilage proteoglycan (PG) aggrecan in adjuvant. This G1-induced arthritis (GIA) model of RA can display Th1- or Th17-skewed cellular responses depending on the route of immunization (ip or id/sc, respectively). We elected to focus on the more aggressive ip-induced form with a Th1 signature phenotype (IFNg). Peptide conjugates composed of an immune cell binding motif (designated DerG or J) and the arthritogenic epitope of human PG (PG70) were constructed. DerG-PG70 (CEL-4000) or J-PG70 vaccine was administered with adjuvant twice (2 weeks apart) to the mice, beginning at the early phase of arthritis. Mice treated with adjuvant only served as controls. Disease severity was monitored by visual scoring of joint inflammation. Three weeks after the second vaccination limbs were processed for histopathology and serum was collected for measurement of pro- and anti-inflammatory cytokines. Spleen cell cultures were set up to examine binding of peptide conjugates to Th cells or antigen-presenting cells (APCs) and to determine Th cell cytokine profiles using flow cytometry and Millipore’s MagPix multiple cytokine assays.

Results:  The CEL-4000 vaccine significantly suppressed arthritis severity and limited joint damage in the ip-induced form of GIA. The other peptide conjugate (J-PG70) or single PG70 and DerG peptides were not therapeutically effective in the disease. Increased ratios of anti-inflammatory cytokines (IL-4 and IL-10) to pro-inflammatory IL-17 were found in the serum of mice vaccinated with CEL-4000 as compared to the other treatment groups. Spleen cells from mice with ip-induced GIA and vaccinated with either CEL-4000 or J-PG70 showed reduced production of Th1 and Th17 signature cytokines as well as other pro-inflammatory mediators in vitro as compared to controls. However, this inhibitory effect was found to be more potent in cell cultures of CEL-4000-treated than J-PG70 treated animals. In vitro cell binding experiments revealed preferential binding of the CEL-4000 peptide conjugate to Th cells whereas J-PG70 bound primarily to APCs.

Conclusion:  Our results suggest that while both peptide vaccines have an influence on the immune system, CEL-4000 powerfully down-modulates pro-inflammatory T-cell responses probably via direct binding to Th cells whereas J-PG70 does it indirectly, and less effectively, via binding to APCs. Robust inhibition of Th1, Th17, and pro-inflammatory pathways, as seen in mice with ip-induced GIA after receiving CEL-4000 vaccine, appears to be necessary for arthritis suppression.


Disclosure: D. Zimmerman, CEL SCI corporation, 1, 9; H. Steiner III, CEL SCI Corporation, 3; R. Carambula, CEL SCI Corporation, 1; A. Markovics, None; A. Finnegan, None; K. Mikecz, None; T. Glant, None.

To cite this abstract in AMA style:

Zimmerman D, Steiner H III, Carambula R, Markovics A, Finnegan A, Mikecz K, Glant T. A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-therapeutic-peptide-vaccine-reduces-pro-inflammatory-responses-and-suppresses-arthritis-in-the-cartilage-proteoglycan-g1-domain-induced-mouse-model-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-therapeutic-peptide-vaccine-reduces-pro-inflammatory-responses-and-suppresses-arthritis-in-the-cartilage-proteoglycan-g1-domain-induced-mouse-model-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology